En­her­tu ex­tends life by three months for some stom­ach can­cer pa­tients, study finds

CHICA­GO — For As­traZeneca and Dai­ichi Sankyo, the an­ti­body-drug con­ju­gate En­her­tu has be­come a re­cur­ring top­ic at the an­nu­al Amer­i­can So­ci­ety of Clin­i­cal On­col­o­gy meet­ing …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER